A detailed history of Founders Capital Management transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Founders Capital Management holds 1,200 shares of BMY stock, worth $69,876. This represents 0.04% of its overall portfolio holdings.

Number of Shares
1,200
Previous 1,200 -0.0%
Holding current value
$69,876
Previous $49,000 26.53%
% of portfolio
0.04%
Previous 0.03%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 10, 2024

BUY
$47.98 - $54.4 $4,798 - $5,440
100 Added 9.09%
1,200 $65,000
Q4 2023

Jan 08, 2024

BUY
$48.48 - $57.85 $4,848 - $5,785
100 Added 10.0%
1,100 $56,000
Q2 2022

Jul 20, 2022

BUY
$72.62 - $79.98 $72 - $79
1 Added 0.1%
1,000 $77,000
Q4 2021

Jan 21, 2022

BUY
$53.63 - $62.52 $5,363 - $6,252
100 Added 11.12%
999 $62,000
Q3 2021

Oct 12, 2021

BUY
$59.17 - $69.31 $23,668 - $27,724
400 Added 80.16%
899 $53,000
Q3 2019

Oct 10, 2019

SELL
$42.77 - $50.71 $29,981 - $35,547
-701 Reduced 58.42%
499 $25,000
Q2 2018

Jul 09, 2018

SELL
$50.53 - $62.98 $2.08 Million - $2.59 Million
-41,159 Reduced 97.17%
1,200 $66,000
Q3 2017

Oct 17, 2017

BUY
$55.23 - $63.74 $2.34 Million - $2.7 Million
42,359
42,359 $2.7 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Founders Capital Management Portfolio

Follow Founders Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Founders Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Founders Capital Management with notifications on news.